University of Illinois

Oklahoma Medical Research Foundation

University of California

The Scripps Research Institute

Other

University of British Columbia

University of Michigan

James H Morrissey

Stephanie A Smith

Galen D Stucky

Damien Kudela

Gary Bernard Braun

Anna May-Masnou

Thomas S Edgington

Philip C Comp

Richard J Travers

Jayachandran N Kizhakkedathu

Rajesh Shenoi

Manu Thomas Kalathottukaren

Roberto Docampo

Nicola J Mutch

Charles T Esmon

Stephen G Sligar

Naomi L Esmon

Alireza Rezaie

Catherine J Baker

Rachel Hemp

Anne Hamik

Vincent S Pureza

A hemostatic composition is provided. The hemostatic composition includes a hemostatically effective amount of a hemostatic agent that includes a nanoparticle and a polyphosphate polymer attached to the nanoparticle. Also provided are medical devices and methods of use to promote blood clotting.

Polyphosphate-functionalized inorganic nanoparticles as hemostatic compositions and methods of use

Provided herein are compositions and methods for quantifying polyphosphates. In particular, provided herein are solution and substrate based assays for quantifying polyphosphates in complex samples.

Assay for quantifying polyphosphates

Provided herein are polymers and methods for their use in binding a phosphate containing biological macromolecules. Specifically, the methods and uses provided herein may be used to inhibit thrombin binding to polyphosphate or as an antithrombotic agent for the treatment of stroke, acute coronary syndrome, pulmonary embolism, atrial fibrillation, venous and arterial thromboembolism, disseminated intravascular coagulation (DIC), deepvein thrombosis (DVT), peripheral artery disease, trauma-induced coagulopathy, extracorporeal circulation, cancer-associated thrombosis, sepsis, septic shock, Systemic Inflammatory Response Syndrome (SIRS), or inflammation.

Antithrombotic compounds, methods and uses thereof

Provided herein are polymers and methods for their use in binding a phosphate containing biological macromolecules. Specifically, the methods and uses provided herein may be used to inhibit thrombin binding to polyphosphate or as an antithrombotic agent for the treatment of stroke, acute coronary syndrome, pulmonary embolism, atrial fibrillation, venous and arterial thromboembolism, disseminated intravascular coagulation (DIC), deep-vein thrombosis (DVT), peripheral artery disease, trauma-induced coagulopathy, extracorporeal circulation, cancer-associated thrombosis, sepsis, septic shock, Systemic Inflammatory Response Syndrome (SIRS), or inflammation.

Methods for stopping or slowing bleeding from a wound are provided; these methods include the step of administering a composition comprising a polyphosphate (polyP) to blood from the wound at the site of the wound. Also provided are methods for slowing fibrinolysis and for blocking the action of Tissue Factor Pathway Inhibitor (TFPI) with the use of polyP.

Coagulation and fibrinolytic cascades modulator

A method for treating a coagulation deficient patient comprises administering an amount of polyP to the patient sufficient to reduce the PT Test value or Dilute PT Test value of the plasma of the patient.

Anticoagulant antagonist and hemophilia procoagulant

A fibrin sealant, comprises (a) thrombin, (b) fibrinogen, (c) polyP, and (d) calcium. The thrombin and the fibrinogen are separated prior to application.

Fibrin sealant

A thromboplastin reagent comprises (i) TF, (ii) a phospholipid, and (iii) a polyP TFPI blocker.

Tissue Factor (natural or recombinant truncated) can be incorporated into stable, soluble nanoscale particles so that activity is maintained. These particles can be used as a reagent in prothrombin clotting time assays or they can be used in therapeutic compositions for use in humans or animals. Therapeutic settings can include supplementation in the case of a genetic deficiency, uncontrolled bleeding, surgical incisions or seepage, thrombocytopenia, soft tissue trauma or other trauma, to effect tumor regression or to inhibit tumor growth.

Tissue factor compositions and methods

A method for determining the concentration of factor VIIa-antithrombin complexes is disclosed which has application to estimating the level of intravascular exposure of tissue factor, assessing patient risk for hypercoagulation or other coagulopathies, and monitoring patients for factor VIIa-antithrombin complexes over time which can reveal changes in risk for hypercoagulation or other coagulopathies and/or effectiveness of anticoagulant therapy. Antibodies suitable for use in an in vitro assay for determining the concentration of factor VIIa-antithrombin complexes and methods for making the same are also disclosed.

Assay for measuring factor viia-antithrombin complexes

A thromboplastin reagent includes tissue factor, Factor VIIa, and a net negatively charged phospholipid. The thromboplastin reagent is a synthetic thromboplastin reagent, and is in dried form.

Growing community of inventors

Champaign, IL, United States of America

James H Morrissey